Home

Paul T Quinlan

CIK 1333277 · General Counsel · last filed 2026-08-14

Paul T Quinlan is a General Counsel who has filed 78 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing, for ORKA, was dated Aug 14, 2026. Across all open-market trades the lifetime net is −$7.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.0M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.01M

Companies

3

Total Filings

78

Lifetime Open-Market Net

-$7.28M

Filer Profile

Reported Address
C/O ORUKA THERAPEUTICS, INC.
855 OAK GROVE AVE., SUITE 100
MENLO PARK, CA 94025
Phone
(650) 438-8958
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ORKA General Counsel 54,274 $92.38 $5.01M -$5.72M 5 2026-08-14
CymaBay Therapeutics, Inc. (CBAY) Delisted General Counsel 0 $32.48 $0 -$1.50M 18 2024-03-22
TerraVia Holdings, Inc. (TVIA) Delisted General Counsel 218,403 — — -$58.2K 5 2017-03-13

Recent Filings

78 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-14 ORKA Notice (144) −71,000 -$7.68M EDGAR
2026-08-14 ORKA Mixed — -$5.04M EDGAR
2026-06-15 ORKA Sell (S) −733 -$51.1K EDGAR
2026-03-17 ORKA Sell (S) −733 -$30.3K EDGAR
2026-01-23 ORKA Grant (A) +32,500 $0 EDGAR
2025-01-24 ORKA Grant (A) — $0 EDGAR
2024-03-22 CymaBay Therapeutics, Inc. (CBAY) Delisted Disp (D) −70,262 $0 EDGAR
2024-03-15 CymaBay Therapeutics, Inc. (CBAY) Delisted Exer (M) +41,824 $330.0K EDGAR
2024-01-26 CymaBay Therapeutics, Inc. (CBAY) Delisted Grant (A) +28,438 $0 EDGAR
2024-01-16 — Notice (144) −5,000 -$117.9K EDGAR
Showing 1–10 of 78
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.